Early prophylactic decompressive hemicraniectomy after endovascular thrombectomy for large hemispheric ischemic infarcts

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study offers early prophylactic decompressive hemicraniectomy to patients with large hemispheric ischemic infarcts after successful endovascular thrombectomy. Eligible adults (18–75 years) have anterior circulation large-vessel occlusion (ICA or MCA‑M1), a large ischemic core on imaging (e.g., ASPECTS ≤5 or ≥50% MCA territory), premorbid mRS ≤1, treatment within 24 hours of last known well, and successful reperfusion (eTICI ≥2b50) without significant midline shift. Surgery is performed soon after EVT to prevent malignant cerebral edema, with primary outcome measures focused on 90‑day functional status, rates of malignant edema, and survival. The trial is led by Xuanwu Hospital in Beijing with an additional participating site in Shandong, China.

Why it matters

Who can join: the full rules

1. Premorbid mRS ≤1;
2. Time from symptom onset to puncture ≤24 hours; including wake-up stroke and unwitnessed stroke. The time at which symptoms began was defined as the "Last Known Well" (LKW).

3.18 to 75 years of age; 4.Internal carotid artery (ICA) or middle cerebral artery (MCA)-M1 occlusion confirmed by computed tomographic angiography (CTA)/ magnetic resonance angiography (MRA)/ digital subtraction angiography (DSA). Patients with involvement of ipsilateral anterior cerebral artery (ACA), MCA or embryonal posterior cerebral artery (PCA) are eligible for inclusion.

5.NIHSS1a ≥ 1 (with the clarification that changes in alertness cannot be attributable to cerebral edema); 6.Meeting any of the following criteria:

1. ASPECTS 3-5 and NIHSS ≥ 30;
2. ASPECTS 0-2; 7.Signs on CT/MRI of an infarct of at least 50% of the middle cerebral artery territory; 8.No midline shift or midline shift \<5mm; 9.Mechanical Thrombectomy and successful recanalization (defined as eTICI ≥2b50); 10.Ability to initiate decompressive hemicraniectomy within 6 hours after completion of mechanical thrombectomy and within 4 hours after randomization; 11.Informed consent obtained from the patient or his/her legal representative.

Exclusion Criteria:

Clinical Exclusion Criteria

1. Any symptoms and signs of brain herniation before randomization, such as pupil anisocoria and unstable vital signs.
2. In the judgment of the investigator, the subject is likely to have supportive care withdrawn in the first day.
3. Commitment to decompressive hemicraniectomy (DHC) prior to enrollment.
4. Severe, sustained hypertension (systolic blood pressure \> 220 mm Hg or diastolic blood pressure \> 110 mm Hg);
5. Baseline blood glucose \<50 mg/dl (2.8 mmol/L) or \>400 mg/dl (22.2 mmol/L);
6. Baseline platelet count \<100 x10\^9/L;
7. Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with international normalized ratio \> 1.7;
8. Severe renal insufficiency, defined as serum creatinine \> 3.0 mg/dl (or 265.2 μmol/l) or glomerular filtration rate \[GFR\] \< 30 ml/min, or patients requiring hemodialysis or peritoneal dialysis;
9. Patients that cannot complete 90-day follow-up (such as no fixed residence, overseas patients, etc.);
10. Suspected vasculitis or septic embolism;
11. Neurological diseases or mental disorders before onset that affect the assessment of the condition;
12. Females who are pregnant or in lactation;
13. Participating in other clinical trials that could confound the evaluation of the study;
14. Subjects who, in the opinion of the investigator, have a life expectancy \<3 months due to conditions not related to current LHI or are unlikely to comply with follow-up requirements. Other conditions that the investigators believe are not suitable for participation or may pose a significant risk to the patient.

Neuroimaging Exclusion Criteria

1. Evidence of other brain diseases such as cerebral trauma, intracranial tumor (except small meningioma), cerebral aneurysm, etc.
2. Evidence of acute ischemic infarction in bilateral anterior circulation territory or involvement of posterior circulation territories (other than in patients with a fetal or near-fetal PCA configuration);
3. Vascular perforation during thrombectomy;
4. The pre-randomization CT findings exhibits evidence of parenchymal hemorrhage 2 intracranial hemorrhage, diffuse severe subarachnoid hemorrhage, or intraventricular hemorrhage. Patients with localized mild subarachnoid hemorrhage, hemorrhagic infarction type1 or 2, and small parenchymal hematoma type 1 without midline shift may be included;

Where it's running

• Liaocheng Brain Hospital
  Shandong, China Recruiting
• Xuanwu Hospital, Capital Medical University.
  Beijing, China Not yet recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Paired VNS: How the Brain and Pupils Respond in Stroke Patients

  This study tests real-time physiologic responses to paired VNS in adults with chronic motor impairment after ischemic stroke to help tailor dosing.

  Recruiting MGH Institute of Health Professions · Boston, Massachusetts · NCT07922200

• NeuroAiD test in mild to moderate ischemic stroke patients

  This study tests whether adding MLC901 (NeuroAiD II) to standard stroke care helps adults who recently had an ischemic stroke recover better than standard care alone.

  Recruiting Phase 4 EVD Pharmacy and Medical Company Limited · Ho Chi Minh City · NCT07828210

• Using IMPROVE to guide carotid revascularisation decisions

  This trial tests whether using the IMPROVE MRI-based score to select patients for carotid revascularisation is as good as standard care based mainly on stenosis degree, among people who have had a recent stroke or TIA due to carotid disease.

  Recruiting Maastricht University Medical Center · Arnhem, Gelderland and 9 other locations · NCT07556887

• High-intensity interval versus moderate continuous exercise for stroke-related muscle loss

  This will test whether high-intensity interval training (HIIT) or moderate-intensity continuous training (MCIT) better helps people 1–6 months after an ischemic stroke who have muscle loss regain muscle mass, strength, walking ability, and quality of life.

  Recruiting Fenerbahce University · Istanbul, Ataşehir · NCT07456956

• Test of adding a very low-dose edoxaban to standard antiplatelet therapy to prevent another stroke in adults 75 and older

  This trial tests whether adding a tiny amount of edoxaban to aspirin or clopidogrel can better prevent a second stroke in people aged 75+ who recently had an ischemic stroke.

  Recruiting Phase 3 Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT07454707

• HR-MRI–Directed Tirofiban Therapy for Late-Window ICAS-LAA Stroke

  We’re testing whether tirofiban plus dual antiplatelet therapy, guided by high-resolution MRI of the brain’s blood vessels, can help people with intracranial large-artery atherosclerosis strokes that begin more than 24 hours after onset.

  Recruiting Phase 3 Weifang Medical University · Weifang, China/Shandong Province · NCT07379190

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.